Compare AVT & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVT | COGT |
|---|---|---|
| Founded | 1921 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.6B |
| IPO Year | 1994 | 2018 |
| Metric | AVT | COGT |
|---|---|---|
| Price | $88.84 | $38.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | ★ $59.33 | $36.21 |
| AVG Volume (30 Days) | 917.6K | ★ 2.0M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $22,200,754,000.00 | $7,871,000.00 |
| Revenue This Year | $14.39 | N/A |
| Revenue Next Year | $5.44 | $1,733.58 |
| P/E Ratio | $35.08 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $44.25 | $10.38 |
| 52 Week High | $95.26 | $43.73 |
| Indicator | AVT | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 52.75 | 52.85 |
| Support Level | $81.80 | $36.38 |
| Resistance Level | $88.16 | $40.67 |
| Average True Range (ATR) | 2.69 | 1.87 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 63.17 | 46.75 |
Avnet Inc is an electronic component technology distributor and solutions provider. It serves customers from startups and mid-sized businesses to enterprise-level original equipment manufacturers (OEMs), electronic manufacturing services (EMS) providers, and original design manufacturers (ODMs). The group operates in the Electronic Components segment and supports high and medium-volume customers to markets, sells, and distributes electronic components, and the Farnell segment supports lower-volume customers that need electronic components quickly to develop, prototype, and test their products. Its geographic regions are the Americas, EMEA, and Asia.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.